Why Is TRULIEVE CANNABIS CO (TRLV) Stock Down Today?

Why TRLV stock is down today

Trulieve Cannabis Co. shares fell 12.17% to $10.90 in a session shaped by regulatory uncertainty. The decline followed a ruling by DEA Chief Judge Derek Julius, who paused the cannabis rescheduling case. This development has raised concerns about the long-term legal and commercial future for cannabis companies, including Trulieve.

What Happened

The stock’s sharp drop came after a judge delayed a decision on whether to reschedule cannabis under federal law. This pause introduces regulatory ambiguity that could affect the industry’s growth trajectory and access to capital. Cantor Fitzgerald maintained its existing stock rating for Trulieve despite the ruling, indicating that the firm sees no immediate change in its outlook for the company. Meanwhile, the broader market saw mixed movements in other sectors, with unrelated stocks like Conagra Brands and Concentrix also experiencing volatility.

What The Data Shows

Trulieve’s fundamentals remain challenging, with a trailing twelve-month revenue decline of 3.9% and a net margin of -41.6%. The stock has traded between $7.82 and $12.93 over the past 52 weeks and is currently near the lower end of that range. The company has printed 14 fresh 52-week lows on September 30, 2026, indicating a prolonged period of weakness. With a beta of 1.76, the stock is more volatile than the broader market, amplifying its response to external shocks like the DEA ruling.

What To Watch

Investors should monitor the rescheduling case for further developments, as any regulatory shift could significantly impact Trulieve’s business. The company’s next earnings report will also be a key event to assess its operational performance and financial resilience.